title: [Prevention of venous thromboembolic events by fondaparinux 2.5mg in patients hospitalized for an acute medical illness. ArchiMed Study].
abstract: OBJECTIVE
  To evaluate the average duration of in-hospital treatment with fondaparinux 2.5mg prescribed for venous thromboprophylaxis in acutely ill medical patients and to describe the treatment population.
  
  
  METHODS
  Prospective, observational, national, multicentre, epidemiological study, performed in France at the request of the Transparency Commission of the French National Health Authority (Haute Autorité de Santé). This is part of a larger study program that also included a study with similar design in the general practice setting. The hospital practice part of the study was conducted by hospital pharmacists who were asked to include the first 15 adult subjects hospitalized in a non-surgical ward for whom fondaparinux 2.5mg was initiated for prophylaxis.
  
  
  RESULTS
  Fifty-three pharmacists (49.5%) included a total of 718 patients. The average age was 71 ± 16 years (47%<75 years old); 54% were women. For 41% of patients, duration of fondaparinux 2.5mg administration ranged from 6 to 14 days. Eighty-five percent of patients had at least one acute illness related to the prescription of fondaparinux 2.5mg for thromboprophylaxis. Ten percent of the population had at least one risk factor listed on the Case Report Form. Characteristics of patients from the hospital practice study differ from those included in the general practice part of the ArchiMed Study program.
  
  
  CONCLUSIONS
  The hospital practice part of the ArchiMed Study, which is similar to "audits of practices", shows that the real-life conditions of prescription of fondaparinux 2.5mg in patients hospitalized are generally in line with guidelines with respect to indication for thromboprophylaxis in acute medical illness.
authors.affiliation: Département de médecine interne et de pneumologie, université européenne de Bretagne, CHU de la Cavale-Blanche, boulevard Tanguy-Prigent, 29609 Brest, France.
authors.forename: C
authors.initials: C
authors.lastname: Leroyer
authors.affiliation: EA 7334 méthodologies et société (REMES), hôpital Louis-Mourier, Sorbonne Paris Cité, université Paris 7, AP-HP, 178, rue des Renouillers, 92700 Colombes, France.
authors.forename: I
authors.initials: I
authors.lastname: Mahé
authors.affiliation: CHU de Nîmes, IURC de Montpellier, 641, avenue du Doyen-Gaston-Giraud, 34093 Montpellier cedex, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Daurès
authors.affiliation: Hôpital Saint-Éloi, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France.
authors.forename: I
authors.initials: I
authors.lastname: Quéré
authors.affiliation: Laboratoire Glaxosmithkline, 100, route de Versailles, 78160 Marly-Le-Roi, France.
authors.forename: C
authors.initials: C
authors.lastname: Aubin
authors.affiliation: Laboratoire Glaxosmithkline, 100, route de Versailles, 78160 Marly-Le-Roi, France.
authors.forename: A
authors.initials: A
authors.lastname: Compagnon
authors.affiliation: Kappa Santé, 4, rue de Cléry, 75002 Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Doussaint
authors.affiliation: Kappa Santé, 4, rue de Cléry, 75002 Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Schück
authors.affiliation: Département de médecine générale, faculté de médecine de Tours, 10, boulevard Tonnellé, BP 3223, 37032 Tours cedex 1, France. Electronic address: denis.pouchain@free.fr.
authors.forename: D
authors.initials: D
authors.lastname: Pouchain
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001510:Bed Rest; D015992:Body Mass Index; D003404:Creatinine / Q000097:blood; D003953:Diagnosis-Related Groups; D004363:Drug Utilization; D005260:Female; D000077425:Fondaparinux; D005602:France; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006748:Hospital Departments; D006801:Humans; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D010607:Pharmacy Service, Hospital / Q000706:statistics & numerical data; D011134:Polysaccharides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D012307:Risk Factors; D012959:Socioeconomic Factors; D019851:Thrombophilia / Q000188:drug therapy* / Q000209:etiology; D054556:Venous Thromboembolism / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D011134:Polysaccharides; D003404:Creatinine; D000077425:Fondaparinux
keywords: Drug utilization; Epidemiology; Hospitalization; Hôpital; Thrombose veineuse; Utilisation médicament; Venous thrombosis; Épidémiologie